SCHEMBL9890653

SCHEMBL9890653

O=C(O)Cc1ccc(F)cc1-c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.49
PTGDR2 Q9Y5Y4 3/20 0.44
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
CHRM1 P11229 5/20 0.43
CHRM3 P20309 5/20 0.43
CHRM2 P08172 1/20 0.43
PTGER1 P34995 1/20 0.43
PTGER4 P35408 1/20 0.43
PTGER3 P43115 1/20 0.43
PTGER2 P43116 1/20 0.43
DCLRE1B Q9H816 1/20 0.42
SUCNR1 Q9BXA5 1/20 0.41
TBXA2R P21731 1/20 0.41
PTGDR Q13258 1/20 0.41
PTGS1 P23219 1/20 0.41
TSHR P16473 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
PDE4B Q07343 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890655 0.89 PPARG (0.49) PPARGPTGDR2AKR1C3AKR1C2CHRM1
SCHEMBL9890669 0.88 SUCNR1 (0.47) PTGDR2CHRM1CHRM3PTGER1PTGER4
SCHEMBL9890666 0.88 PTGDR2 (0.50) PPARGPTGDR2PTGER1PTGER4PTGER3
SCHEMBL9890733 0.87 ICMT (0.44) PPARGCHRM1CHRM3CHRM2CYP3A4
SCHEMBL9890681 0.87 PTGDR2 (0.45) PPARGPTGDR2AKR1C3AKR1C2CHRM1
SCHEMBL9890651 0.85 PTGS1 (0.51) PPARGPTGDR2PTGER1PTGER4PTGER3
SCHEMBL9890642 0.82 CHRM1 (0.57) CHRM1CHRM3PTGER1PTGER4PTGER3
SCHEMBL9890670 0.81 ACLY (0.50) PTGDR2AKR1C3AKR1C2CHRM1SUCNR1
SCHEMBL9890674 0.80 SUCNR1 (0.46) PPARGPTGDR2AKR1C3AKR1C2CHRM1
SCHEMBL9890667 0.80 TSHR (0.47) PPARGPTGDR2TBXA2RPTGDRPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PPARG 2516/4885PTGDR2 1062/4885AKR1C3 191/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PPARG 2516/4885PTGDR2 1062/4885AKR1C3 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.